207 related articles for article (PubMed ID: 31132401)
21. Minimal Physiologically Based Pharmacokinetic-Pharmacodynamic (mPBPK-PD) Model of
Ayyar VS; Song D; Zheng S; Carpenter T; Heald DL
J Pharmacol Exp Ther; 2021 Nov; 379(2):134-146. PubMed ID: 34413198
[TBL] [Abstract][Full Text] [Related]
22. Learning and confirming with preclinical studies: modeling and simulation in the discovery of GDC-0917, an inhibitor of apoptosis proteins antagonist.
Wong H; Gould SE; Budha N; Darbonne WC; Kadel EE; La H; Alicke B; Halladay JS; Erickson R; Portera C; Tolcher AW; Infante JR; Mamounas M; Flygare JA; Hop CE; Fairbrother WJ
Drug Metab Dispos; 2013 Dec; 41(12):2104-13. PubMed ID: 24041744
[TBL] [Abstract][Full Text] [Related]
23. Preclinical Pharmacokinetics and Translational Pharmacokinetic/Pharmacodynamic Modeling of M8891, a Potent and Reversible Inhibitor of Methionine Aminopeptidase 2.
Lignet F; Friese-Hamim M; Jaehrling F; El Bawab S; Rohdich F
Pharm Res; 2023 Dec; 40(12):3011-3023. PubMed ID: 37798538
[TBL] [Abstract][Full Text] [Related]
24. Discovery of (S)-1-(1-(Imidazo[1,2-a]pyridin-6-yl)ethyl)-6-(1-methyl-1H-pyrazol-4-yl)-1H-[1,2,3]triazolo[4,5-b]pyrazine (volitinib) as a highly potent and selective mesenchymal-epithelial transition factor (c-Met) inhibitor in clinical development for treatment of cancer.
Jia H; Dai G; Weng J; Zhang Z; Wang Q; Zhou F; Jiao L; Cui Y; Ren Y; Fan S; Zhou J; Qing W; Gu Y; Wang J; Sai Y; Su W
J Med Chem; 2014 Sep; 57(18):7577-89. PubMed ID: 25148209
[TBL] [Abstract][Full Text] [Related]
25. Pharmacokinetic-pharmacodynamic modeling of biomarker response and tumor growth inhibition to an orally available cMet kinase inhibitor in human tumor xenograft mouse models.
Yamazaki S; Skaptason J; Romero D; Lee JH; Zou HY; Christensen JG; Koup JR; Smith BJ; Koudriakova T
Drug Metab Dispos; 2008 Jul; 36(7):1267-74. PubMed ID: 18381487
[TBL] [Abstract][Full Text] [Related]
26. Preclinical pharmacokinetic/pharmacodynamic models of gefitinib and the design of equivalent dosing regimens in EGFR wild-type and mutant tumor models.
Wang S; Guo P; Wang X; Zhou Q; Gallo JM
Mol Cancer Ther; 2008 Feb; 7(2):407-17. PubMed ID: 18281523
[TBL] [Abstract][Full Text] [Related]
27. Preclinical characterization of OSI-027, a potent and selective inhibitor of mTORC1 and mTORC2: distinct from rapamycin.
Bhagwat SV; Gokhale PC; Crew AP; Cooke A; Yao Y; Mantis C; Kahler J; Workman J; Bittner M; Dudkin L; Epstein DM; Gibson NW; Wild R; Arnold LD; Houghton PJ; Pachter JA
Mol Cancer Ther; 2011 Aug; 10(8):1394-406. PubMed ID: 21673091
[TBL] [Abstract][Full Text] [Related]
28. Translational PK/PD Modeling of Tumor Growth Inhibition and Target Inhibition to Support Dose Range Selection of the LMP7 Inhibitor M3258 in Relapsed/Refractory Multiple Myeloma.
Lignet F; Esdar C; Walter-Bausch G; Friese-Hamim M; Stinchi S; Drouin E; El Bawab S; Becker AD; Gimmi C; Sanderson MP; Rohdich F
J Pharmacol Exp Ther; 2023 Jan; 384(1):163-172. PubMed ID: 36273822
[TBL] [Abstract][Full Text] [Related]
29. Preclinical PK/PD model for the combinatorial use of dexamethasone and sulpiride in the treatment of breast cancer.
Yao QY; Li J; Chen R; Yao Y; Xue JS; Chen WJ; Lu W; Zhou TY
Acta Pharmacol Sin; 2019 Dec; 40(12):1596-1602. PubMed ID: 31165782
[TBL] [Abstract][Full Text] [Related]
30. Human microdosing and mice xenograft data of AGM-130 applied to estimate efficacious doses in patients.
Park WS; Park GJ; Han S; Ban S; Park MY; Kim SH; Kim SM; Kim YC; Kim HS; Shin YG; Yim DS
Cancer Chemother Pharmacol; 2017 Aug; 80(2):363-369. PubMed ID: 28660432
[TBL] [Abstract][Full Text] [Related]
31. Mechanistic understanding of translational pharmacokinetic-pharmacodynamic relationships in nonclinical tumor models: a case study of orally available novel inhibitors of anaplastic lymphoma kinase.
Yamazaki S; Lam JL; Zou HY; Wang H; Smeal T; Vicini P
Drug Metab Dispos; 2015 Jan; 43(1):54-62. PubMed ID: 25349124
[TBL] [Abstract][Full Text] [Related]
32. Preclinical absorption, distribution, metabolism, excretion, and pharmacokinetic-pharmacodynamic modelling of N-(4-(3-((3S,4R)-1-ethyl-3-fluoropiperidine-4-ylamino)-1H-pyrazolo[3,4-b]pyridin-4-yloxy)-3-fluorophenyl)-2-(4-fluorophenyl)-3-oxo-2,3-dihydropyridazine-4-carboxamide, a novel MET kinase inhibitor.
Liederer BM; Berezhkovskiy LM; Dean BJ; Dinkel V; Peng J; Merchant M; Plise EG; Wong H; Liu X
Xenobiotica; 2011 Apr; 41(4):327-39. PubMed ID: 21182395
[TBL] [Abstract][Full Text] [Related]
33. Translational and pharmacokinetic-pharmacodynamic application for the clinical development of GDC-0334, a novel TRPA1 inhibitor.
Chan P; Ding HT; Liederer BM; Mao J; Belloni P; Chen L; Gao SS; Joseph V; Yang X; Lin JS; Mitra MS; Putnam WS; Quartino A; Bauer RN; Pan L
Clin Transl Sci; 2021 Sep; 14(5):1945-1954. PubMed ID: 34058071
[TBL] [Abstract][Full Text] [Related]
34. Bench to bedside translation of antibody drug conjugates using a multiscale mechanistic PK/PD model: a case study with brentuximab-vedotin.
Shah DK; Haddish-Berhane N; Betts A
J Pharmacokinet Pharmacodyn; 2012 Dec; 39(6):643-59. PubMed ID: 23151991
[TBL] [Abstract][Full Text] [Related]
35. Time-dependent pharmacokinetics of dexamethasone and its efficacy in human breast cancer xenograft mice: a semi-mechanism-based pharmacokinetic/pharmacodynamic model.
Li J; Chen R; Yao QY; Liu SJ; Tian XY; Hao CY; Lu W; Zhou TY
Acta Pharmacol Sin; 2018 Mar; 39(3):472-481. PubMed ID: 29119968
[TBL] [Abstract][Full Text] [Related]
36. Translational pharmacokinetic-pharmacodynamic modeling from nonclinical to clinical development: a case study of anticancer drug, crizotinib.
Yamazaki S
AAPS J; 2013 Apr; 15(2):354-66. PubMed ID: 23250669
[TBL] [Abstract][Full Text] [Related]
37. Novel targeting of phospho-cMET overcomes drug resistance and induces antitumor activity in multiple myeloma.
Moschetta M; Basile A; Ferrucci A; Frassanito MA; Rao L; Ria R; Solimando AG; Giuliani N; Boccarelli A; Fumarola F; Coluccia M; Rossini B; Ruggieri S; Nico B; Maiorano E; Ribatti D; Roccaro AM; Vacca A
Clin Cancer Res; 2013 Aug; 19(16):4371-82. PubMed ID: 23804425
[TBL] [Abstract][Full Text] [Related]
38. Correlation of pharmacokinetics with the antitumor activity of Cetuximab in nude mice bearing the GEO human colon carcinoma xenograft.
Luo FR; Yang Z; Dong H; Camuso A; McGlinchey K; Fager K; Flefleh C; Kan D; Inigo I; Castaneda S; Rose WC; Kramer RA; Wild R; Lee FY
Cancer Chemother Pharmacol; 2005 Nov; 56(5):455-64. PubMed ID: 15947929
[TBL] [Abstract][Full Text] [Related]
39. 18FDG-PET predicts pharmacodynamic response to OSI-906, a dual IGF-1R/IR inhibitor, in preclinical mouse models of lung cancer.
McKinley ET; Bugaj JE; Zhao P; Guleryuz S; Mantis C; Gokhale PC; Wild R; Manning HC
Clin Cancer Res; 2011 May; 17(10):3332-40. PubMed ID: 21257723
[TBL] [Abstract][Full Text] [Related]
40. Pharmacokinetic/Pharmacodynamic Modeling of the Anti-Cancer Effect of Dexamethasone in Pancreatic Cancer Xenografts and Anticipation of Human Efficacious Doses.
Yao Y; Yao Q; Fu Y; Tian X; An Q; Yang L; Su H; Lu W; Hao C; Zhou T
J Pharm Sci; 2020 Feb; 109(2):1169-1177. PubMed ID: 31655033
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
